WO2008086452A3 - Treatment and prevention of alzheimer's disease - Google Patents

Treatment and prevention of alzheimer's disease Download PDF

Info

Publication number
WO2008086452A3
WO2008086452A3 PCT/US2008/050683 US2008050683W WO2008086452A3 WO 2008086452 A3 WO2008086452 A3 WO 2008086452A3 US 2008050683 W US2008050683 W US 2008050683W WO 2008086452 A3 WO2008086452 A3 WO 2008086452A3
Authority
WO
WIPO (PCT)
Prior art keywords
disease
alzheimer
prevention
treatment
patient
Prior art date
Application number
PCT/US2008/050683
Other languages
French (fr)
Other versions
WO2008086452A2 (en
Inventor
Richard Mayeux
Ekaterina Rogaeva
George-Hyslop Peter St
Lindsay Farrer
Original Assignee
Univ Columbia
Trustees Of Boston Uuniversity
Univ Toronto
Richard Mayeux
Ekaterina Rogaeva
George-Hyslop Peter St
Lindsay Farrer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Columbia, Trustees Of Boston Uuniversity, Univ Toronto, Richard Mayeux, Ekaterina Rogaeva, George-Hyslop Peter St, Lindsay Farrer filed Critical Univ Columbia
Publication of WO2008086452A2 publication Critical patent/WO2008086452A2/en
Publication of WO2008086452A3 publication Critical patent/WO2008086452A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4515—Non condensed piperidines, e.g. piperocaine having a butyrophenone group in position 1, e.g. haloperidol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone

Abstract

The present invention is directed to a method for treating Alzheimer's disease in a patient who is also determined to have less than about 90% of the SORL1 level determined in a normal subject, by administering to the patient one or more of compounds that increase SORL1 expression in the patient.
PCT/US2008/050683 2007-01-10 2008-01-09 Treatment and prevention of alzheimer's disease WO2008086452A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US87966507P 2007-01-10 2007-01-10
US60/879,665 2007-01-10
US89361007P 2007-03-07 2007-03-07
US60/893,610 2007-03-07

Publications (2)

Publication Number Publication Date
WO2008086452A2 WO2008086452A2 (en) 2008-07-17
WO2008086452A3 true WO2008086452A3 (en) 2008-10-16

Family

ID=39609366

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/050683 WO2008086452A2 (en) 2007-01-10 2008-01-09 Treatment and prevention of alzheimer's disease

Country Status (1)

Country Link
WO (1) WO2008086452A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101614558B1 (en) 2008-04-27 2016-04-22 하. 룬드벡 아크티에셀스카브 Crystal structure of human sortilin and uses thereof for identifying ligands to sortilin
EP2323687A2 (en) * 2008-09-11 2011-05-25 H. Lundbeck A/S Method of upregulating sorla for the treatment of alzheimer's disease
WO2010065117A1 (en) * 2008-12-03 2010-06-10 Massachusetts Institute Of Technology Inhibition of hdac2 to promote memory
JP5841234B2 (en) 2011-03-31 2016-01-13 ザ プロクター アンド ギャンブルカンパニー Systems, models, and methods for identifying and evaluating skin active agents effective in the treatment of dandruff / seborrheic dermatitis
JP2015527630A (en) 2012-06-06 2015-09-17 ザ プロクター アンド ギャンブルカンパニー Cosmetic identification system and method for hair / scalp care composition
WO2014113495A1 (en) 2013-01-15 2014-07-24 The Trustees Of Columbia University In The City Of New York Activation or reactivation of ache
US10849992B1 (en) 2015-04-07 2020-12-01 Alector Llc Methods of screening for sortilin binding antagonists
ES2899227T3 (en) 2015-04-07 2022-03-10 Alector Llc Anti-sortilin antibodies and methods of using them
ES2940311T3 (en) 2018-07-13 2023-05-05 Alector Llc Anti-sortilin antibodies and methods of use thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040138187A1 (en) * 2002-08-28 2004-07-15 Reading Christopher L. Therapeutic treatment methods

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040138187A1 (en) * 2002-08-28 2004-07-15 Reading Christopher L. Therapeutic treatment methods

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ANDERSON ET AL.: "Neuronal sorting protein-related receptor sorLA͞LR11 regulates processing of the amyloid precursor protein", PNAS, vol. 102, 2005, pages 13461 - 13466, XP055351569 *
LIM ET AL.: "A Diet Enriched with the Omega-3 Fatty Acid Docosahexaenoic Acid Reduces Amyloid Burden in an Aged Alzheimer Mouse Model", J. NEUROSCIENCE., vol. 25, 2005, pages 3032 - 3040, XP002369001 *
MA ET AL.: "Omega-3 Fatty Acid Docosahexaenoic Acid Increases SorLA/LR11, a Sorting Protein with Reduced Expression in Sporadic Alzheimer's Disease (AD): Relevance to AD Prevention", J. NEUROSCI., vol. 27, 2007, pages 14299 - 14307, XP055351560 *
RACCHI ET AL.: "Acetylcholinesterase inhibitors: novel activities of old molecules", PHARMACOL. RES ., vol. 50, 2004, pages 441 - 451, XP002998429 *
ROGAEVA ET AL.: "The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease", NAT. GENET., vol. 39, no. 2, 2007, pages 168 - 177, XP055050412 *

Also Published As

Publication number Publication date
WO2008086452A2 (en) 2008-07-17

Similar Documents

Publication Publication Date Title
WO2008086452A3 (en) Treatment and prevention of alzheimer's disease
WO2008150490A3 (en) Uses and compositions for treatment of psoriasis and crohn's disease
WO2009050506A3 (en) Combination 059
WO2009127642A3 (en) Use of lrrk2 inhibitors for neurodegenerative diseases
WO2010071826A3 (en) Methods for treating osteoclast-related disease, compounds and compositions thereof
WO2008033464A3 (en) Azetidinone derivatives for the treatment of disorders of the lipid metabolism
WO2006093348A3 (en) Method and composition for treating peripheral vascular diseases
WO2005076819A3 (en) Chlorite in the treatment of neurodegenerative disease
WO2010030781A3 (en) Aromatic carboxylic acid derivatives for treatment and prophylaxis of gastrointestinal diseases including colon cancer
ZA200810113B (en) Method for the treatment and prevention of ocular disorders
WO2006098603A3 (en) Composition comprising isoorientin for suppressing histamine
WO2010065792A3 (en) Treatment of erythropoietin (epo) related diseases by inhibition of natural antisense transcript to epo
WO2009137465A3 (en) Compositions for treatment or prevention of pathological cardiac remodeling and heart failure
WO2014078575A3 (en) Novel orally bioavailable breathing control modulating compounds, and methods of using same
WO2006009975A3 (en) Histamine to treat disorders affecting muscle function
HK1114876A1 (en) Arthrospira-based compositions and uses thereof
WO2010075280A3 (en) Coumarin-based compounds for the treatment of alzheimer's disease and cancer
MX367131B (en) 3,6-disubstituted xanthylium salts as medicaments.
WO2007058805A3 (en) Compositions and methods for treating cns disorders
WO2004110380A3 (en) Treatment of immune-mediated disorders with active vitamin d compounds alone or in combination with other therapeutic agents
WO2008157787A3 (en) Hydroxylated tolans and related compounds in the treatment of cancer
MX2009007247A (en) Method for the treatment of conditions associated with increased 5-lipoxygenase and/or leukotriene activity.
WO2007120485A3 (en) Methods of treating pain with alkylxanthines and antiepileptics and compositions for use therefor
WO2005082375A3 (en) Treatment of interstitial cystitis with vitamin d compounds
WO2008157747A8 (en) Use of inhibition of exonuclease 1 in methods for therapy and diagnostic of neurodegenerative diseases, eye diseases, and mitochondrial disorders

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08727492

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08727492

Country of ref document: EP

Kind code of ref document: A2